Latest News and Press Releases

MENLO PARK, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...

MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions...

MENLO PARK, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions...

DATA PRESENTED AT THE 2022 AMERICAN ACADEMY OF OPTOMETRY MEETINGMEIBOMIAN GLAND FUNCTION IMPROVES BY 63% AND DRY EYE SYMPTOMS REDUCED BY 44% THROUGH 12 MONTHS MENLO PARK, Calif., Dec. 08, 2022 ...

MENLO PARK, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...

MENLO PARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...

Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery.Despite glaucoma medications and prior microbypass stenting, target IOP may no...

MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...

Randomized, controlled clinical trial data on advanced dry eye patients from the OLYMPIA trial recently published in Clinical OphthalmologyStudy authors concluded that the TearCare procedure delivered...

MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI...